Biotech

Biotech narratives get much clearer when the team separates platform ambition from program evidence. The public resources that help most are the ones that connect translational milestones, clinical operations, and regulatory planning instead of letting each discipline pretend it can work alone.

The classic mistake is overselling platform breadth before the lead program has earned it. Another is treating regulatory strategy like a writing exercise that happens after the science is done. A healthy workflow names the program hypothesis, maps preclinical and translational milestones to the next financing or partnering decision, and then builds clinical and regulatory readiness in parallel. The work gets expensive when those streams only meet at the deadline.

If you want a cleaner start, build your notes around biotech, therapeutics, and the real examples behind biotech strategy gets stronger when teams separate platform promise from program evidence.. Those records will outlast the summary you write about them later.

Open alongside this question:
- FDA drug development and approval process: fda.gov/drugs/development-approval-process-drugs
A grounding document for the path from development to review and approval.
- Addgene protocols: addgene.org/protocols/
Practical wet-lab documentation that is genuinely useful for day-to-day work.
- NIH video archive: youtube.com/@NIH/videos
Webinars and talks that help keep the science connected to real public research practice.